Celyad Oncology SA (FRA:1C0)

Market Cap	14.10M -27.6%
Revenue (ttm)	21.00K -88.7%
Net Income	830.00K
EPS	0.02
Shares Out	n/a
PE Ratio	16.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	44
Open	0.2750
Previous Close	0.2770
Day's Range	0.2750 - 0.2750
52-Week Range	0.1285 - 0.4630
Beta	n/a
RSI	47.96
Earnings Date	Apr 2, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1C0